US7440855B2 - Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis - Google Patents
Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis Download PDFInfo
- Publication number
- US7440855B2 US7440855B2 US09/928,191 US92819101A US7440855B2 US 7440855 B2 US7440855 B2 US 7440855B2 US 92819101 A US92819101 A US 92819101A US 7440855 B2 US7440855 B2 US 7440855B2
- Authority
- US
- United States
- Prior art keywords
- network
- reaction
- metabolite
- interest
- reactions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 80
- 238000003068 pathway analysis Methods 0.000 title description 9
- 230000003115 biocidal effect Effects 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims abstract description 140
- 230000004907 flux Effects 0.000 claims abstract description 116
- 230000037361 pathway Effects 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 89
- 230000008569 process Effects 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 34
- 238000004458 analytical method Methods 0.000 claims abstract description 32
- 239000011159 matrix material Substances 0.000 claims abstract description 27
- 239000002207 metabolite Substances 0.000 claims description 76
- 238000005842 biochemical reaction Methods 0.000 claims description 60
- 238000012217 deletion Methods 0.000 claims description 57
- 230000037430 deletion Effects 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 23
- 239000012620 biological material Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 244000052769 pathogen Species 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 230000002939 deleterious effect Effects 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 230000003292 diminished effect Effects 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 abstract description 20
- 238000013459 approach Methods 0.000 abstract description 6
- 230000008030 elimination Effects 0.000 abstract description 6
- 238000003379 elimination reaction Methods 0.000 abstract description 6
- 239000004599 antimicrobial Substances 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000758 substrate Substances 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 6
- 238000012067 mathematical method Methods 0.000 description 6
- 238000012269 metabolic engineering Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 238000013178 mathematical model Methods 0.000 description 4
- 230000004656 cell transport Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000019525 primary metabolic process Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005183 dynamical system Methods 0.000 description 2
- 239000003256 environmental substance Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/30—Dynamic-time models
Definitions
- the present invention generally concerns the identification of (i) pathways and (ii) critical points in, and (iii) the generation of mathematical models of, existing and proposed cellular metabolic networks comprised of biochemical reactions or mechanisms with genetic or non-genetic associations.
- biochemical reaction networks primarily involve the use of enzymes derived from particular genes whose chromosomal location and function have been characterized, as well as enzymes inferred to be present based on similarity of their genomic sequence to the genomic sequences of enzyme-coding genes in other organisms.
- enzymes derived from particular genes whose chromosomal location and function have been characterized, as well as enzymes inferred to be present based on similarity of their genomic sequence to the genomic sequences of enzyme-coding genes in other organisms.
- convex analysis There exists one particular type of mathematical analysis of cellular biochemical reaction networks called “convex analysis”. need definition.
- Some of the principles of convex analysis were previously used by Schuster to find “elementary nodes”, or reactions within the biochemical reaction networks. See Schuster, S., T. Dandekar and D. A. Fell, 1999, Detection of elementary flux modes in biochemical networks: a promising tool for pathway analysis and metabolic engineering, Trends Biotechnology 17(2): 53-60. See also Schuster, S. and C. Hilgetag, 1994, On elementary flux modes in biochemical reaction systems at steady state. J. Biological Systems 2(2): 165-182. Finally see Schuster, S., C. Hilgetag, J. H. Woods and D. A. Fell, 1996, Elementary modes of functioning in biochemical networks.
- the mathematics associated with convex analysis may be used to determine the minimal set of biochemical pathways by which some particular capability of the biochemical reaction network is realized. These pathways satisfy both (i) mass balance constraints (associated with stoichiometry) and (ii) directional constraints placed on reactions (associated with thermodynamics).
- the same mathematical computational tools can be used to improve the design and engineering of organisms for industrial application such as the production of bio-commodities.
- the tools permit recognition of how an beneficial process and pathway of the biochemical reaction network might be augmented or accentuated.
- Liao, et al. report research where all of the elementary modes for a reduced reaction network in Escherichia coli were calculated and studied to determine the optimal flux distributions through a central metabolism that redirected carbon flow to the pathways from aromatic amino acid production. Reactions that did not appear in the optimal pathways were considered indispensable, while those that did appear in the optimal pathways were candidates for over-expression.
- the present invention provides a general framework and system for the identification of all the minimal sets of reactions that, when removed from a biochemical reaction network, will render the network unable to reach its particular production objectives.
- biochemical reaction networks are conventionally (i) constructed from genomic and biochemical data and (ii) described by a stoichiometric matrix. Together, the constraints on the directions in which reactions can proceed and the stoichiometric matrix correspond to a mathematical system of linear equations and linear inequalities, which system can be studied using convex analysis.
- sets of extreme pathways are defined that are used to represent all of the possible steady states which the network can achieve. By removing a single reaction in the network all of the pathways that utilize this reaction are also removed. To remove the ability of the network to reach a particular objective, all of the extreme pathways that reach this objective must be removed.
- the calculating of the generating vectors of the flux cone preferably ensues by specific mathematical manipulations within the more general mathematical process of convex analysis. More particularly, the specific preferred convex analysis of the present invention consists of calculating any of (i) a conical basis, (ii) a convex basis, (iii) a linear basis, or (iv) a combination of any of conical and convex and linear bases.
- the method of the present invention may be used, for example, to produce an output of interest which consists of one or more functional properties of interest in the analyzed biochemical production network.
- the reaction sets show how these one or more functional properties of interest can be diminished or eliminated. If the output of interest consists of, for example, but one single functional property of interest in the analyzed biochemical production network then the reaction sets show how this functional property of interest can be diminished or eliminated.
- the reaction network analyzed is an organism producing both desired bio-molecules of value and un-desired bio-molecules of no value
- the metabolite of interest produced by the organism is defined to be the un-desired and valueless bio-molecules
- the method of the present invention using the reaction set can be directed to metabolically re-engineering the organism to fail of those reactions that produce the particular metabolite that is un-desired and valueless.
- production of un-desired valueless bio-molecules can be eliminated while continued production of desired valued bio-molecules is permitted.
- the reaction network analyzed is an organism producing desired bio-molecules of value by each of two or more—multiple—metabolic routes
- the metabolite of interest is defined to be the valued molecule as is produced by one only—preferred—route of the multiple routes by which the organism is capable of producing this molecule
- the method of the present invention using the reaction set can be directed to metabolically re-engineering the organism to fail of those reactions that produce the metabolite of interest via inefficient route(s), therein by eliminating production of metabolite via this route (these routes) nonetheless that the metabolite is of value.
- Production of the desired metabolite by one or more alternative one(s) of the multiple metabolic routes is left intact, and may even be accentuated.
- reaction set produced by the mathematical method of the present invention to be a valuable tool.
- the reaction set shows how to preclude, or to obstruct, or to accentuate individual biochemical pathways within the organism as lead to the production of particular metabolites. It is hard to ask for more than this: a complete quantitative, mathematical, model as to the biochemical reactions of the cell.
- the method of the present invention thus consists of using this convex hull—a mathematical construction—to represent the capabilities of a metabolic genotype.
- the unique generating, edge, vectors that define and that span the convex hull represent systemically independent extreme pathways of the metabolic, life, processes of the metabolic genotype.
- the convex hull is mathematically solved, again by a specific application of the more general process of convex analysis, so as to derive a particular solution that represents a metabolic phenotype.
- This particular solution is, mathematically, a particular point described by a flux vector lying within the interior of the convex hull.
- the mathematical solving is repeated until a complete set of particular solutions, corresponding to a set of flux vectors each lying within the convex hull, is derived.
- This set of solutions corresponds to all the pathways by which a particular metabolic phenotype is realized.
- the method of the present invention can be employed on the genotype of a pathogenic, disease-causing, organism.
- the method of the present invention preferably continues with the development of drugs that, by obstructing those biochemical reactions of the genotype of the pathogenic organism that lead to a particular, disease-inducing, solution of the genotype, serve to eliminate the deleterious, disease-causing, phenotype of the pathogenic organism.
- this the method of the present invention can be employed on the genotype of an organism producing both (i) desired bio-molecules of value and (ii) undesired bio-molecules of no value.
- the method of the present invention preferably continues with metabolically re-engineering the organism so as to obstruct those biochemical reactions of the genotype of the pathogenic organism that lead to that particular solution where the phenotype produces the undesired valueless bio-molecules, eliminating production of these undesired valueless bio-molecules while permitting continued production of desired valued bio-molecules.
- the present invention is embodied in a method of analyzing a metabolic network.
- the method consists of first identifying all biochemical reactions occurring in the metabolic network, including any directions thereof. Then all exchange fluxes are specified, including any associated directional restraints attendant upon metabolites of the identified biochemical reactions.
- a stoichiometric matrix where each column in the matrix corresponds to a reaction, or flux, and where each row corresponds to a different metabolite involved in the metabolic network is next created.
- This created stoichiometric matrix represents, in all its columns and rows, the collective biochemical reactions, being a form of chemical conversion, and the collective cellular transport processes of the metabolic network, which cellular transport processes are how the metabolites enter and leave the metabolic network.
- the analyzing consists of solving the equations 1-3 in convex space as a convex polyhedral cone in n-dimensional space emanating from the origin of the space.
- Every point on the convex polyhedral cone may in particular be represented by
- the analyzing consists of calculating the conical hull of the flux cone as representing the extreme pathways in the metabolic network.
- the method may further continue by determining from the calculated pathways critical biochemical reactions, or sets of biochemical reactions, that are required for the metabolic network to attain a particular objective or group of objectives—as is (are) represented by one or more particular points on the flux cone.
- FIG. 1 is a flow diagram illustrating one procedure of the present invention for determining one set, or the entire collection, of minimal deletion sets that eliminate particular production capabilities of interest in a metabolic network.
- FIG. 2 is a geometric representation of the flux cone of the mathematical method of the present invention shown in three-dimensions where the entire unbounded flux cone is spanned by the generating vectors representing the capabilities of a metabolic genotype.
- FIG. 3 consisting of FIGS. 3 a - 3 c , are respectively a graph of an exemplary metabolic reactions scheme, a legend to the mathematical representation of the scheme, and table of the extreme pathways as collectively define a metabolic genotype and phenotype in the context of convex analysis, where, more particularly,
- FIG. 3( a ) shows a hypothetical reaction network comprised of a series of internal and exchange fluxes, functioning to generate appropriate ratios of metabolites C, D, and E for incorporation into biomass represented as the GRO metabolite;
- FIG. 3( b ) shows a mathematical translation of the reaction network into the steady-state mass balances and constraints placed on all fluxes that define the solution domain
- FIG. 4 is a table 1 showing the set of extreme pathways *p 1 , . . . , p 10 ) for the reaction scheme shown in FIG. 3 .
- FIG. 5 is a graph showing normalized values for the objective flux (b z ) for all single and double deletion combinations of the network described in FIG. 3 .
- the present invention relates to systems and methods for (i) identifying deletion sets in a target organism's metabolic network (ii) based on a pathway analysis (iii) mathematically derived from (iv) a list of reactions associated with convexity, which reactions are a partial or a complete representation of reactions in a cell.
- systems and methods described herein can be implemented on any conventional host computer system, such as those based on Intel® microprocessors and running Microsoft Windows operating systems. Other systems, such as those using the UNIX or LINUX operating system and based on IBM®, DEC® or Motorola® microprocessors are also contemplated.
- the systems and methods described herein can also be implemented to run on client-server systems and wide-area networks, such as the Internet.
- the software of the invention normally runs from instructions stored in a memory on the host computer system.
- a memory can be a hard disk, Random Access Memory, Read Only Memory and Flash Memory.
- Other types of memories are also contemplated to function within the scope of the invention.
- minimal deletion sets These lethal or minimal sets of reactions and the genes coding for the gene products of these reactions are herein referred to as minimal deletion sets.
- these pathways can be used to calculate every possible deletion set in a network for a given set of input and output conditions. Any combination of genetic deletions that would be lethal to an organism must contain a subset of genes that form a minimal deletion set. Therefore if the combined loss of gene A and B is lethal to an organism, where A and B alone are not essential genes, then the set is a minimal deletion set, making every superset of this also a deletion set (such as the loss of gene A, B and C).
- the removal of a set of internal fluxes from the network eliminates the ability of the network to produce the desired metabolic objective such as precursors for growth, and the cell can not obtain these precursors from its environment, then the removal of this set of fluxes constitutes a minimal deletion set that has potential as an antimicrobial drug target or combination of targets. All of these minimal deletion sets can be calculated based on the process described herein and the appropriate genetic targets identified from the network composition.
- Pathway 1 and 2 use both A and C to reach the growth objective while pathway 3 and 4 only use C, and 5 , 6 , 7 , and 8 use only metabolite A as their input.
- Pathway 9 and 10 correspond to internal cycles in the network and are ignored from further consideration, as they do not add functionality to the network. Each pathway satisfies the mass balances and flux constraints placed on the network in FIG. 3(B)
- the minimal deletion sets for growth on substrate C is simply ⁇ (v 5 ), (v 8 ), (v 6 ,v 7 ) ⁇ .
- the minimal deletion sets are ⁇ (v 8 ), (v 1 ,v 5 ), (v 3 ,v 5 ), (v 6 , v 7 ) ⁇ .
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Evolutionary Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Urology & Nephrology (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
S·v=0 (Equation 1)
where S refers to the stoichiometric matrix of the system and v is the flux vector;
vi≧0, ∀i (Equation 2)
where vi corresponds to the flux value of the ith reaction; and
αi ≦b i≦βi (Equation 3)
where αi and βi are ether zero of negative and positive infinity, respectively, based on the direction of exchange flux, and bi corresponds to the ith exchange flux.
S·v=0 (Equation 1)
where S refers to the stoichiometric matrix of the system, v is the flux vector. This equation simply states that over long times, the formation fluxes of a metabolite must be balanced by the degradation fluxes. Otherwise, significant amounts of the metabolite will accumulate inside the metabolic network. Applying
vi≧0, ∀i (Equation 2)
where vi corresponds to the flux value of the ith reaction. The constraints on the exchange fluxes depend on the status of the determined source or sink on the associated metabolite, or similarly on the input and output status of the metabolite. This can be expressed in
αi ≦b i≦βi (Equation 3)
Under the existence of a source(input) only αi is set to negative infinity and βi is set to zero, whereas if only a sink(output) exists on the metabolite αi is set to zero and βi is set to positive infinity. If both a source and sink are present then the exchange flux is bi-directional with αi set to negative infinity and βi is set to positive infinity leaving the exchange flux unconstrained.
Thus the set of extreme pathways is analogous to a basis/coordinate system that can be used to describe a position in space. These pathways are said to conically span or generate the set of all pathways as any pathway and/or distribution of fluxes can be written as a non-negative linear combination of the pi's. The pathway vector w corresponds to the coordinate vector relative to the set of extreme pathways. It provides the weight given to each pathway in a particular flux distribution (v).
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/928,191 US7440855B2 (en) | 2001-08-11 | 2001-08-11 | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/928,191 US7440855B2 (en) | 2001-08-11 | 2001-08-11 | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20030032576A1 US20030032576A1 (en) | 2003-02-13 |
| US7440855B2 true US7440855B2 (en) | 2008-10-21 |
Family
ID=25455858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/928,191 Expired - Lifetime US7440855B2 (en) | 2001-08-11 | 2001-08-11 | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US7440855B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011034263A1 (en) * | 2009-09-18 | 2011-03-24 | 한국과학기술원 | Method for predicting a drug target in pathogenic microorganisms using an essential metabolite |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004034022A2 (en) * | 2002-10-08 | 2004-04-22 | Case Western Reserve University | Shape optimization to solve inverse problems and curve/model fitting problems |
| US20050251346A1 (en) * | 2004-03-29 | 2005-11-10 | Ilie Fishtik | Method and apparatus for reaction route graphs for reaction mechanism and kinetics modeling |
| US9239903B2 (en) | 2012-03-13 | 2016-01-19 | Gabriele Scheler | Determination of output of biochemical reaction networks |
| CN102663272A (en) * | 2012-03-14 | 2012-09-12 | 天津大学 | Network construction and analysis method for oxidized bacterium gluconicum genome scale metabolism |
| CN114639443B (en) * | 2022-04-07 | 2025-01-28 | 广西大学 | A method for sorting branch pathways in metabolic networks based on atom cluster tracking |
-
2001
- 2001-08-11 US US09/928,191 patent/US7440855B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Schilling et al. ((Biotechnol. Bioeng. (2000/2001) vol. 71, pp. 286-306; published online Mar. 30, 2001). * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011034263A1 (en) * | 2009-09-18 | 2011-03-24 | 한국과학기술원 | Method for predicting a drug target in pathogenic microorganisms using an essential metabolite |
| WO2011034397A3 (en) * | 2009-09-18 | 2011-10-06 | 한국과학기술원 | Method for predicting drug targets and screening for drugs for pathogenic microorganisms using essential metabolites |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030032576A1 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vilhekar et al. | Artificial intelligence in genetics | |
| Sapoval et al. | Current progress and open challenges for applying deep learning across the biosciences | |
| Schilling et al. | Metabolic pathway analysis: basic concepts and scientific applications in the post‐genomic era | |
| Wang et al. | BERMUDA: a novel deep transfer learning method for single-cell RNA sequencing batch correction reveals hidden high-resolution cellular subtypes | |
| Hie et al. | Computational methods for single-cell RNA sequencing | |
| Hädicke et al. | OptMDFpathway: Identification of metabolic pathways with maximal thermodynamic driving force and its application for analyzing the endogenous CO2 fixation potential of Escherichia coli | |
| Hoffman et al. | variancePartition: interpreting drivers of variation in complex gene expression studies | |
| Wilke et al. | The biology of digital organisms | |
| Sîrbu et al. | Comparison of evolutionary algorithms in gene regulatory network model inference | |
| JP2014211907A (en) | Human metabolic models and methods | |
| Hu et al. | Genomics and systems biology of mammalian cell culture | |
| Bhat et al. | Whole-cell modeling and simulation: A brief survey | |
| Tyagi et al. | Future of bioinformatics in India: A survey | |
| Zeng et al. | CLAIRE: a contrastive learning-based predictor for EC number of chemical reactions | |
| Pinzon et al. | Mathematical Framework Behind the Reconstruction and Analysis of Genome Scale Metabolic Models: W. Pinzon et al. | |
| US7440855B2 (en) | Identification of antibiotic targets and critical points in metabolic networks based on pathway analysis | |
| Prado et al. | Accounting for shared covariates in semi-parametric Bayesian additive regression trees | |
| Jungreuthmayer et al. | Avoiding the enumeration of infeasible elementary flux modes by including transcriptional regulatory rules in the enumeration process saves computational costs | |
| Galuzzi et al. | Coupling constrained-based flux sampling and clustering to tackle cancer metabolic heterogeneity | |
| Denaro et al. | A pipeline for testing drug mechanism of action and combination therapies: From microarray data to simulations via Linear-In-Flux-Expressions: Testing four-drug combinations for tuberculosis treatment | |
| Cheng et al. | Ancestral population genomics with jocx, a coalescent hidden Markov model | |
| Sikdar | Robust meta-analysis for large-scale genomic experiments based on an empirical approach | |
| Balakrishnan et al. | Gene-LLMs: a comprehensive survey of transformer-based genomic language models for regulatory and clinical genomics | |
| Wang et al. | Using SCDL for integrating tools and data for complex biomedical applications | |
| Wendering et al. | COMMIT: Consideration of metabolite leakage and community composition improves microbial community models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHILLING, CHRISTOPHE;REEL/FRAME:021501/0868 Effective date: 20010802 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| SULP | Surcharge for late payment | ||
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |